Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model

OncoImmunology

Volumn 7, Issue 1, 2018, Pages

  Bocca, Paola ^a   Di Carlo, Emma ^b   Caruana, Ignazio ^c   Emionite, Laura ^d   Cilli, Michele ^d   De Angelis, Biagio ^c   Quintarelli, Concetta ^c,e   Pezzolo, Annalisa ^a   Raffaghello, Lizzia ^a   Morandi, Fabio ^a   Locatelli, Franco ^c,f   Pistoia, Vito ^c   Prigione, Ignazia ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

angiogenesis; bevacizumab; CAR T cells; immunotherapy; neuroblastoma

Indexed keywords

EID: 85030559977     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1378843     Document Type: Article

References (56)

1. Cheung NKV, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411. doi:10.1038/nrc3526. PMID:23702928
2. Maris JM. Medical Progress: Recent Advances in Neuroblastoma. New Engl J Med. 2010;362:2202–11. doi:10.1056/NEJMra0804577. PMID:20558371
3. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol. 2011;21:229–37. doi:10.1016/j.semcancer.2011.09.012. PMID:21971567
4. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol. 2012;24:633–9. doi:10.1016/j.coi.2012.06.004. PMID:22818942
5. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. New Engl J Med. 2010;363:1324–34. doi:10.1056/NEJMoa0911123. PMID:20879881
6. De Angelis B, Caruana I, Orlando D, Boffa I, Guercio M, Sinibaldi M, Polito V, Pagliara D, Moseley A, Brenner MK, et al. Generation of T lymphocytes genetically modified to express third generation GD2-specific chimeric antigen receptor (CAR) with CD28/4.1BB costimulation to improve anti-tumor efficacy of adoptive T cell therapy for patients with neuroblastoma (NB). Bone Marrow Transpl. 2016;51:S58–S9.
7. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, et al. CAR T cells administered in combination with Lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214–2224. doi:10.1016/j.ymthe.2017.05.012. PMID:28602436
8. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu EL, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050–6. doi:10.1182/blood-2011-05-354449. PMID:21984804
9. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu EL, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–70. doi:10.1038/nm.1882. PMID:18978797
10. Beatty GL, O'Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Therapeut. 2016;166:30–9. doi:10.1016/j.pharmthera.2016.06.010.
11. Brentjens RJ, Davila ML, Riviere I, Park J, Wang XY, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra3. doi:10.1126/scitranslmed.3005930.
12. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. New Engl J Med. 2013;368:1509–18. doi:10.1056/NEJMoa1215134. PMID:23527958
13. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1–18. doi:10.1146/annurev.med.57.121304.131306. PMID:16409133
14. Meister B, Grunebach F, Bautz F, Brugger W, Fink FM, Kanz L, Mohle R. Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer. 1999;35:445–9. doi:10.1016/S0959-8049(98)00387-6. PMID:10448297
15. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 1996;14:405–14. doi:10.1200/JCO.1996.14.2.405. PMID:8636750
16. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer. 2002;102:351–4. doi:10.1002/ijc.10742. PMID:12402304
17. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307. doi:10.1038/nature10144. PMID:21593862
18. Potente M, Gerhardt H, Carmeliet P. Basic and Therapeutic Aspects of Angiogenesis. Cell. 2011;146:873–87. doi:10.1016/j.cell.2011.08.039. PMID:21925313
19. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–74. doi:10.1038/nature04483. PMID:16355214
20. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor-growth Invivo. Nature. 1993;362:841–4. doi:10.1038/362841a0. PMID:7683111
21. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–91. doi:10.1038/nrc2403. PMID:18596824
22. Ferrara N. VEGF as a therapeutic target in cancer. Oncology-Basel. 2005;69:11–6. doi:10.1159/000088479.
23. Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol. 2012;9:297–303. doi:10.1038/nrclinonc.2012.8. PMID:22330688
24. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385–403. doi:10.1038/nrd.2015.17. PMID:26775688
25. Roy Choudhury S, Karmakar S, Banik NL, Ray SK. Targeting angiogenesis for controlling neuroblastoma. J Oncol. 2012;2012:782020. doi:10.1155/2012/782020. PMID:21876694
26. Segerstrom L, Fuchs D, Backman U, Holmquist K, Christofferson R, Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res. 2006;60:576–81. doi:10.1203/01.pdr.0000242494.94000.52. PMID:16988184
27. Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005;228:171–9. doi:10.1016/j.canlet.2005.01.049. PMID:15927358
28. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417–27. doi:10.1038/nrd3455. PMID:21629292
29. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13:3942–50. doi:10.1158/1078-0432.CCR-07-0278. PMID:17606728
30. Jain RK. Antiangiogenesis Strategies Revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605–22. doi:10.1016/j.ccell.2014.10.006. PMID:25517747
31. Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. doi:10.1038/ncomms12624. PMID:27571927
32. Shrimali RK, Yu ZY, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171–80. doi:10.1158/0008-5472.CAN-10-0153. PMID:20631075
33. Huang YH, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943–8. doi:10.1158/0008-5472.CAN-12-4354. PMID:23440426
34. Huang YH, Yuan JP, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. P Natl Acad Sci USA. 2012;109:17561–6. doi:10.1073/pnas.1215397109.
35. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 Blockade. Mol Ther. 2016;24:1135–49. doi:10.1038/mt.2016.63. PMID:27019998
36. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90. doi:10.1038/nm.3838. PMID:25939063
37. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015;33:1688–96. doi:10.1200/JCO.2014.58.0225. PMID:25800760
38. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21:524–U158. doi:10.1038/nm.3833. PMID:25849134
39. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b. J Immunother. 2010;33:780–8. doi:10.1097/CJI.0b013e3181ee6675. PMID:20842059
40. Moon EK, Carpenito C, Sun J, Wang LCS, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM. Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor. Clin Cancer Res. 2011;17:4719–30. doi:10.1158/1078-0432.CCR-11-0351. PMID:21610146
41. Nishio N, Dotti G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. Oncoimmunology. 2015;4:e988098. doi:10.4161/21505594.2014.988098. PMID:25949885
42. Yu LL, Wu XM, Cheng ZY, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest Ophth Vis Sci. 2008;49:522–7. doi:10.1167/iovs.07-1175.
43. Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer. 2011;129:2935–44. doi:10.1002/ijc.25960. PMID:22030616
44. Bernassola F, Scheuerpflug C, Herr I, Krammer PH, Debatin KM, Melino G. Induction of apoptosis by IFN gamma in human neuroblastoma cell lines through the CD95/CD95 L autocrine circuit. Cell Death Differ. 1999;6:652–60. doi:10.1038/sj.cdd.4400537. PMID:10453076
45. Fulda S, Debatin KM. IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene. 2002;21:2295–308. doi:10.1038/sj.onc.1205255. PMID:11948413
46. Pistoia V, Bianchi G, Borgonovo G, Raffaghello L. Cytokines in neuroblastoma: from pathogenesis to treatment. Immunotherapy-Uk. 2011;3:895–907. doi:10.2217/imt.11.80.
47. Di Carlo E, Bocca P, Emionite L, Cilli M, Cipollone G, Morandi F, Raffaghello L, Pistoia V, Prigione I. Mechanisms of the Antitumor Activity of Human V gamma 9 V delta 2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. Mol Ther. 2013;21:1034–43. doi:10.1038/mt.2013.38. PMID:23481325
48. Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70. doi:10.3389/fonc.2014.00070. PMID:24765614
49. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223–5. doi:10.4161/onci.21335. PMID:23243584
50. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7 H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8(+) T cells. Cancer Res. 2004;64:1140–5. doi:10.1158/0008-5472.CAN-03-3259. PMID:14871849
51. Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, et al. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology. 2016;5:e1064578. doi:10.1080/2162402X.2015.1064578. PMID:26942080
52. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130–44. doi:10.1172/JCI83092. PMID:27454297
53. Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, Suzuki M. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res. 2017;77:2040–51. doi:10.1158/0008-5472.CAN-16-1577. PMID:28235763
54. Modak S, Kushner BH, Basu E, Roberts SS, Cheung NV. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatr Blood Cancer. 2017;64. doi:10.1002/pbc.26448.
55. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009;15:5852–60. doi:10.1158/1078-0432.CCR-08-3163. PMID:19737958
56. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24:1160–70. doi:10.1038/leu.2010.75. PMID:20428207